Cancer and Metastasis Reviews

, Volume 22, Issue 4, pp 395–403 | Cite as

Role of MAP kinase in tumor progression and invasion

  • Kaladhar B. Reddy
  • Sanaa M. Nabha
  • Natasha Atanaskova


Activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) pathway is a frequent event in tumorigenesis. MAPKs have been implicated in cell migration, proteinase-induction, regulation of apoptosis, and angiogenesis, events that are essential for successful completion of metastasis. In this review, we discuss the potential role that MAPKs play in metastasis by regulating cell migration, proteinase-induction and apoptosis.

apoptosis invasion MAPK metastasis migration proteinases 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Reddy KB, Krueger JS, Kondapaka SB, Diglio CA: Mitogen-activated protein kinase (MAPK) regulates the expression of progelatinase B (MMP-9) in breast epithelial cells. Int J Cancer 82: 268–273. 1999Google Scholar
  2. 2.
    Krueger JS, Keshamouni VG, Atanaskova N, Reddy KB: Temporal and quantitative regulation of mitogen-activated protein kinase (MAPK) modulates cell motility and invasion. Oncogene 20: 4209–4218. 2001Google Scholar
  3. 3.
    Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, Shimada Y, Ari-i S, Wada H, Fujimoto J, Kohno M: Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18: 813–822, 1999Google Scholar
  4. 4.
    Sivaraman VS, Wang H, Nuovo GJ, Malbon CC: Hyperexpression of mitogen-activated protein kinase in human breast cancer. J Clin Invest 99: 1478–1483, 1997Google Scholar
  5. 5.
    Salh B, Marotta A, Matthewson C, Ahluwalia M, Flint J, Owen D, Pelech S: Investigation of the Mek-MAP kinase-Rsk pathway in human breast cancer. Anticancer Res 19: 731–740, 1999Google Scholar
  6. 6.
    Mueller H, Flury N, Eppenberger-Castori S, Kueng W, David F, Eppenberger U: Potential prognostic value of mitogen-activated protein kinase activity for disease-free survival of primary breast cancer patients. Int J Cancer 89: 384–388, 2000Google Scholar
  7. 7.
    Wilsbacher JL, Goldsmith EJ, Cobb MH: Phosphorylation of MAP kinases by MAP/ERK involves multiple regions of MAP kinases. J Biol Chem 274: 16988–16994, 1999Google Scholar
  8. 8.
    Ahn NG: The MAP kinase cascade. Discovery of a new signal transduction pathway. Mol Cell Biochem 127–128: 201–209, 1993Google Scholar
  9. 9.
    Widmann C, Gibson S, Jarpe MB, Johnson GL: Mitogenactivated protein kinase: Conservation of a three-kinase module from yeast to human. Physiol Rev 79: 143–180, 1999Google Scholar
  10. 10.
    Garrington TP, Johnson GL: Organization and regulation of mitogen-activated protein kinase signaling pathways. Curr Opin Cell Biol 11: 211–218, 1999Google Scholar
  11. 11.
    Lenormand P, Brondello JM, Brunet A, Pouyssegur J: Growth factor-induced p42/p44 MAPK nuclear translocation and retention requires both MAPK activation and neosynthesis of nuclear anchoring proteins. J Cell Biol 142: 625–633, 1998Google Scholar
  12. 12.
    Adachi M, Fukuda M, Nishida E: Nuclear export of MAP kinase (ERK) involves a MAP kinase kinase (MEK)-dependent active transport mechanism. J Cell Biol 148: 849–856, 2000Google Scholar
  13. 13.
    Groom LA, Sneddon AA, Alessi DR, Dowd S, Keyse SM: Differential regulation of the MAP, SAP and RK/p38 kinases by Pyst1, a novel cytosolic dual-specificity phosphatase. Embo J 15: 3621–3632, 1996Google Scholar
  14. 14.
    Chernoff J: Protein tyrosine phosphatases as negative regulators of mitogenic signaling. J Cell Physiol 180: 173–181, 1999Google Scholar
  15. 15.
    Zheng CF, Guan KL: Dephosphorylation and inactivation of the mitogen-activated protein kinase by a mitogeninduced Thr/Tyr protein phosphatase. J Biol Chem 268: 16116–16119, 1993Google Scholar
  16. 16.
    Chu Y, Solski PA, Khosravi-Far R, Der CJ, Kelly K: The mitogen-activated protein kinase phosphatases PAC1, MKP-1, and MKP-2 have unique substrate specificities and reduced activity in vivo toward the ERK2 sevenmaker mutation. J Biol Chem 271: 6497–6501, 1996Google Scholar
  17. 17.
    Gonzalez FA, Raden DL, Rigby MR, Davis RJ: Heterogeneous expression of four MAP kinase isoforms in human tissues. FEBS Lett 304: 170–178, 1992Google Scholar
  18. 18.
    Cheng M, Boulton TG, Cobb MH: ERK3 is a constitutively nuclear protein kinase. J Biol Chem 271: 8951–8958, 1996Google Scholar
  19. 19.
    Zhou G, Bao ZQ, Dixon JE: Components of a new human protein kinase signal transduction pathway. J Biol Chem 270: 12665–12669, 1995Google Scholar
  20. 20.
    Lee JD, Ulevitch RJ, Han J: Primary structure of BMK1: A new mammalian mapkinase. Biochem Biophys Res Commun 213: 715–724, 1995Google Scholar
  21. 21.
    Kato Y, Tapping RI, Huang S, Watson MH, Ulevitch RJ, Lee JD: Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor. Nature 395: 713–716, 1998Google Scholar
  22. 22.
    English JM, Pearson G, Hockenberry T, Shivakumar L, White MA, Cobb MH: Contribution of the ERK5/MEK5 pathway to Ras/Raf signaling and growth control. J Biol Chem 274: 31588–31592, 1999Google Scholar
  23. 23.
    Abe MK, Kuo WL, Hershenson MB, Rosner MR: Extracellular signal-regulated kinase 7 (ERK7), a novel ERK with a C-terminal domain that regulates its activity, its cellular localization, and cell growth. Mol Cell Biol 19: 1301–1312, 1999Google Scholar
  24. 24.
    Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH: Mitogen-activated protein (MAP) kinase pathways: Regulation and physiological functions. Endocr Rev 22: 153–183, 2001Google Scholar
  25. 25.
    Pawson T, Scott JD: Signaling through scaffold, anchoring, and adaptor proteins. Science 278: 2075–2080, 1997Google Scholar
  26. 26.
    Schaeffer HJ, Catling AD, Eblen ST, Collier LS, Krauss A, Weber MJ: MP1: A MEK binding partner that enhances enzymatic activation of the MAP kinase cascade. Science 281: 1668–1671, 1998Google Scholar
  27. 27.
    Elion EA: Routing MAP kinase cascades. Science 281: 1625–1626, 1998Google Scholar
  28. 28.
    Dickens M, Rogers JS, Cavanagh J, Raitano A, Xia Z, Halpern JR, Greenberg ME, Sawyers CL, Davis RJ: A cytoplasmic inhibitor of the JNK signal transduction pathway. Science 277: 693–696, 1997Google Scholar
  29. 29.
    Whitmarsh AJ, Cavanagh J, Tournier C, Yasuda J, Davis RJ: A mammalian scaffold complex that selectively mediates MAP kinase activation. Science 281: 1671–1674, 1998Google Scholar
  30. 30.
    Yan M, Dai T, Deak JC, Kyriakis JM, Zon LI, Woodgett JR, Templeton DJ: Activation of stress-activated protein kinase by MEKK1 phosphorylation of its activator SEK1. Nature 372: 798–800, 1994Google Scholar
  31. 31.
    Matrisian LM: Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 6: 121–125, 1990Google Scholar
  32. 32.
    Matrisian LM: The matrix-degrading metalloproteinases. Bioessays 14: 455–463, 1992Google Scholar
  33. 33.
    Rochefort H, Capony F, Garcia M: Cathepsin D: A protease involved in breast cancer metastasis. Cancer Metastasis Rev 9: 321–331, 1990Google Scholar
  34. 34.
    Coutts AS, Murphy LC: Elevated mitogen-activated protein kinase activity in estrogen-nonresponsive human breast cancer cells. Cancer Res 58: 4071–4074, 1998Google Scholar
  35. 35.
    McCawley LJ, Li S, Wattenberg EV, Hudson LG: Sustained activation of the mitogen-activated protein kinase pathway. A mechanism underlying receptor tyrosine kinase specificity for matrix metalloproteinase-9 induction and cell migration. J Biol Chem 274: 4347–4353, 1999Google Scholar
  36. 36.
    Adeyinka A, Nui Y, Cherlet T, Snell L, Watson PH, Murphy LC: Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression. Clin Cancer Res 8: 1747–1753, 2002Google Scholar
  37. 37.
    Overall CM, Lopez-Otin C: Strategies for mmp inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2: 657–672, 2002Google Scholar
  38. 38.
    Ree AH, Bjornland K, Brunner N, Johansen HT, Pedersen KB, Aasen AO, Fodstad O: Regulation of tissue-degrading factors and in vitro invasiveness in progression of breast cancer cells. Clin ExpMetastasis 16: 205–215, 1998Google Scholar
  39. 39.
    Gum R, Lengyel E, Juarez J, Chen JH, Sato H, Seiki M, Boyd D: Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences. J Biol Chem 271: 10672–10680, 1996Google Scholar
  40. 40.
    Kondapaka SB, Fridman R, Reddy KB: Epidermal growth factor and amphiregulin up-regulate matrix metalloproteinase-9 (MMP-9) in human breast cancer cells. Int J Cancer 70: 722–726, 1997Google Scholar
  41. 41.
    Brogley MA, Cruz M, Cheung HS: Basic calcium phosphate crystal induction of collagenase 1 and stromelysin expression is dependent on a p42/44 mitogen-activated protein kinase signal transduction pathway. J Cell Physiol 180: 215–224, 1999Google Scholar
  42. 42.
    Mazumdar A, Adam L, Boyd D, Kumar R: Heregulin regulation of urokinase plasminogen activator and its receptor: Human breast epithelial cell invasion. Cancer Res 61: 400–405, 2001Google Scholar
  43. 43.
    Yao J, Xiong S, Klos K, Nguyen N, Grijalva R, Li P, Yu D: Multiple signaling pathways involved in activation of matrix metalloproteinase-9 (MMP-9) by heregulin-beta1 in human breast cancer cells. Oncogene 20: 8066–8074, 2001Google Scholar
  44. 44.
    Vu TH, Werb Z: Matrix metalloproteinases: Effectors of development and normal physiology. Genes Dev 14: 2123–2133, 2000Google Scholar
  45. 45.
    Yu Q, Stamenkovic I: Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 14: 163–176, 2000Google Scholar
  46. 46.
    Stamenkovic I: Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol 10: 415–433, 2000Google Scholar
  47. 47.
    Sehgal I, Baley PA, Thompson TC: Transforming growth factor beta1 stimulates contrasting responses in metastatic versus primary mouse prostate cancer-derived cell lines in vitro. Cancer Res 56: 3359–3365, 1996Google Scholar
  48. 48.
    Rao JS, Steck PA, Mohanam S, Stetler-Stevenson WG, Liotta LA, Sawaya R: Elevated levels of M(r) 92,000 type IV collagenase in human brain tumors. Cancer Res 53: 2208–2211, 1993Google Scholar
  49. 49.
    Jones JL, Glynn P, Walker RA: Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas. J Pathol 189: 161–168, 1999Google Scholar
  50. 50.
    Hujanen ES, Vaisanen A, Zheng A, Tryggvason K, Turpeenniemi-Hujanen T: Modulation of M(r) 72,000 and M(r) 92,000 type-IV collagenase (gelatinase A and B) gene expression by interferons alpha and gamma in human melanoma. Int J Cancer 58: 582–586, 1994Google Scholar
  51. 51.
    Nakajima M, Welch DR, Wynn DM, Tsuruo T, Nicolson GL: Serum and plasma M(r) 92,000 progelatinase levels correlate with spontaneous metastasis of rat 13762NF mammary adenocarcinoma. Cancer Res 53: 5802–5807, 1993Google Scholar
  52. 52.
    Lozonschi L, Sunamura M, Kobari M, Egawa S, Ding L, Matsuno S: Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models. Cancer Res 59: 1252–1258, 1999Google Scholar
  53. 53.
    Garbisa S, Pozzatti R, Muschel RJ, Saffiotti U, Ballin M, Goldfarb RH, Khoury G, Liotta LA: Secretion of type IV collagenolytic protease and metastatic phenotype: induction by transfection with c-Ha-ras but not c-Ha-ras plus Ad2-E1a. Cancer Res 47: 1523–1528, 1987Google Scholar
  54. 54.
    Davies B, Brown PD, East N, Crimmin MJ, Balkwill FR: A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 53: 2087–2091, 1993Google Scholar
  55. 55.
    Sternlicht MD, Werb Z: How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17: 463–516, 2001Google Scholar
  56. 56.
    Yeow KM, Phillips BW, Beaudry PP, Leco KJ, Murphy G, Edwards DR: Expression of MMPs and TIMPs in mammalian cells. Methods Mol Biol 151: 181–189, 2001Google Scholar
  57. 57.
    Egeblad M, Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161–174, 2002Google Scholar
  58. 58.
    Lauffenburger DA, Horwitz AF: Cell migration: A physically integrated molecular process. Cell 84: 359–369, 1996Google Scholar
  59. 59.
    Genersch E, Schneider DW, Sauer G, Khazaie K, Schuppan D, Lichtner RB: Prevention of EGF-modulated adhesion of tumor cells to matrix proteins by specific EGF receptor inhibition. Int J Cancer 75: 205–209, 1998Google Scholar
  60. 60.
    Zeigler ME, Chi Y, Schmidt T, Varani J: Role of ERK and JNK pathways in regulating cell motility and matrix metalloproteinase 9 production in growth factor-stimulated human epidermal keratinocytes. J Cell Physiol 180: 271–284, 1999Google Scholar
  61. 61.
    Hartmann G, Weidner KM, Schwarz H, Birchmeier W: The motility signal of scatter factor/hepatocyte growth factor mediated through the receptor tyrosine kinase met requires intracellular action of Ras. J Biol Chem 269: 21936–21939, 1994Google Scholar
  62. 62.
    Klemke RL, Yebra M, Bayna EM, Cheresh DA: Receptor tyrosine kinase signaling required for integrin alpha v beta 5-directed cell motility but not adhesion on vitronectin. J Cell Biol 127: 859–866, 1994Google Scholar
  63. 63.
    Howe AK, Juliano RL: Distinct mechanisms mediate the initial and sustained phases of integrin-mediated activation of the Raf/MEK/mitogen-activated protein kinase cascade. J Biol Chem 273: 27268–27274, 1998Google Scholar
  64. 64.
    Tan JL, Ravid S, Spudich JA: Control of nonmuscle myosins by phosphorylation. Annu Rev Biochem 61: 721–759, 1992Google Scholar
  65. 65.
    Klemke RL, Cai S, Giannini AL, Gallagher PJ, de Lanerolle P, Cheresh DA: Regulation of cell motility by mitogen-activated protein kinase. J Cell Biol 137: 481–492, 1997Google Scholar
  66. 66.
    Ridley AJ: Rho GTPases and cell migration. J Cell Sci 114: 2713–2722, 2001Google Scholar
  67. 67.
    Chrzanowska-Wodnicka M, Burridge K: Rho-stimulated contractility drives the formation of stress fibers and focal adhesions. J Cell Biol 133: 1403–1415, 1996Google Scholar
  68. 68.
    Kaibuchi K, Kuroda S, Amano M: Regulation of the cytoskeleton and cell adhesion by the Rho family GTPases in mammalian cells. Annu Rev Biochem 68: 459–486, 1999Google Scholar
  69. 69.
    Amano M, Fukata Y, Kaibuchi K: Regulation and functions of Rho-associated kinase. ExpCell Res 261: 44–51, 2000Google Scholar
  70. 70.
    Totsukawa G, Yamakita Y, Yamashiro S, Hartshorne DJ, Sasaki Y, Matsumura F: Distinct roles of ROCK (Rho-kinase) and MLCK in spatial regulation of MLC phosphorylation for assembly of stress fibers and focal adhesions in 3T3 fibroblasts. J Cell Biol 150: 797–806, 2000Google Scholar
  71. 71.
    Tanimura S, Nomura K, Ozaki K, Tsujimoto M, Kondo T, Kohno M: Prolonged nuclear retention of activated extracellular signal-regulated kinase 1/2 is required for hepatocyte growth factor-induced cell motility. J Biol Chem 277: 28256–28264, 2002Google Scholar
  72. 72.
    Collins P, Webb C: Estrogen hits the surface. Nat Med 5: 1130–1131, 1999Google Scholar
  73. 73.
    Migliaccio A, Di Domenico M, Castoria G, de Falco A, Bontempo P, Nola E, Auricchio F: Tyrosine kinase/p21ras/ MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. Embo J 15: 1292–1300, 1996Google Scholar
  74. 74.
    Song RX, McPherson RA, Adam L, Bao Y, Shupnik M, Kumar R, Santen RJ: Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation. Mol Endocrinol 16: 116–127, 2002Google Scholar
  75. 75.
    Bi R, Broutman G, Foy MR, Thompson RF, Baudry M: The tyrosine kinase and mitogen-activated protein kinase pathways mediate multiple effects of estrogen in hippocampus. Proc Natl Acad Sci USA 97: 3602–3607, 2000Google Scholar
  76. 76.
    Rambo CO, Szego CM: Estrogen action at endometrial membranes: alterations in luminal surface detectable within seconds. J Cell Biol 97: 679–685, 1983Google Scholar
  77. 77.
    Santen RJ, Song RX, McPherson R, Kumar R, Adam L, Jeng MH, Yue W: The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol 80: 239–256, 2002Google Scholar
  78. 78.
    Price JT, Tiganis T, Agarwal A, Djakiew D, Thompson EW: Epidermal growth factor promotes MDA-MB-231 breast cancer cell migration through a phosphatidylinositol 30-kinase and phospholipase C-dependent mechanism. Cancer Res 59: 5475–5478, 1999Google Scholar
  79. 79.
    Reddy KB, Keshamouni VG, Chen YQ: The level of tyrosine kinase activity regulates the expression of p21/ WAF1 in cancer cells. Int J Oncol 15: 301–306, 1999Google Scholar
  80. 80.
    Su B, Karin M: Mitogen-activated protein kinase cascades and regulation of gene expression. Curr Opin Immunol 8: 402–411, 1996Google Scholar
  81. 81.
    Gulli LF, Palmer KC, Chen YQ, Reddy KB: Epidermal growth factor-induced apoptosis in A431 cells can be reversed by reducing the tyrosine kinase activity. Cell Growth Differ 7: 173–178, 1996Google Scholar
  82. 82.
    Thompson CB: Apoptosis in the pathogenesis and treatment of disease. Science 267: 1456–1462, 1995Google Scholar
  83. 83.
    Raff MC, Barres BA, Burne JF, Coles HS, Ishizaki Y, Jacobson MD: programd cell death and the control of cell survival: lessons from the nervous system. Science 262: 695–700, 1993Google Scholar
  84. 84.
    Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X: Cytochrome c and dATPdependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91: 479–489, 1997Google Scholar
  85. 85.
    Ashkenazi A: Targeting death and decoy receptors of the tumor-necrosis factor superfamily. Nat Rev Cancer 2: 420–430, 2002Google Scholar
  86. 86.
    Eastman A: Survival factors, intracellular signal transduction, and the activation of endonucleases in apoptosis. Semin Cancer Biol 6: 45–52, 1995Google Scholar
  87. 87.
    Stadheim TA, Xiao H, Eastman A: Inhibition of extracellular signal-regulated kinase (ERK) mediates cell cycle phase independent apoptosis in vinblastine-treated ML-1 cells. Cancer Res 61: 1533–1540, 2001Google Scholar
  88. 88.
    Tran SE, Holmstrom TH, Ahonen M, Kahari VM, Eriksson JE: MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors. J Biol Chem 276: 16484–16490, 2001Google Scholar
  89. 89.
    Holmstrom TH, Schmitz I, Soderstrom TS, Poukkula M, Johnson VL, Chow SC, Krammer PH, Eriksson JE: MAPK/ERK signaling in activated T cells inhibits CD95/ Fas-mediated apoptosis downstream of DISC assembly. Embo J 19: 5418–5428, 2000Google Scholar
  90. 90.
    Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME: Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270: 1326–1331, 1995Google Scholar
  91. 91.
    Greene LA: Nerve growth factor prevents the death and stimulates the neuronal differentiation of clonal PC12 pheochromocytoma cells in serum-free medium. J Cell Biol 78: 747–755, 1978Google Scholar
  92. 92.
    Buckley S, Driscoll B, Barsky L, Weinberg K, Anderson K, Warburton D: ERK activation protects against DNA damage and apoptosis in hyperoxic rat AEC2. Am J Physiol 277: L159–166, 1999Google Scholar
  93. 93.
    Erhardt P, Schremser EJ, Cooper GM: B-Raf inhibits programd cell death downstream of cytochrome c release from mitochondria by activating the MEK/Erk pathway. Mol Cell Biol 19: 5308–5315, 1999Google Scholar
  94. 94.
    Anderson CN, Tolkovsky AM: A role for MAPK/ERK in sympathetic neuron survival: protection against a p53-dependent, JNK-independent induction of apoptosis by cytosine arabinoside. J Neurosci 19: 664–673, 1999Google Scholar
  95. 95.
    Sarker M, Ruiz-Ruiz C, Robledo G, Lopez-Rivas A: Stimulation of the mitogen-activated protein kinase pathway antagonizes TRAIL-induced apoptosis downstream of BID cleavage in human breast cancer MCF-7 cells. Oncogene 21: 4323–4327, 2002Google Scholar
  96. 96.
    Scheid MP, Duronio V: Dissociation of cytokine-induced phosphorylation of bad and activation of PKB/akt: involvement of MEK upstream of bad phosphorylation. Proc Natl Acad Sci USA 95: 7439–7444, 1998Google Scholar
  97. 97.
    Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ: Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 80: 285–291, 1995Google Scholar
  98. 98.
    Chao DT, Linette GP, Boise LH, White LS, Thompson CB, Korsmeyer SJ: Bcl-XL and Bcl-2 repress a common pathway of cell death. J Exp Med 182: 821–828, 1995Google Scholar
  99. 99.
    Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ: Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14–3–3 not BCL-X(L). Cell 87: 619–628, 1996Google Scholar

Copyright information

© Kluwer Academic Publishers 2003

Authors and Affiliations

  • Kaladhar B. Reddy
    • 1
  • Sanaa M. Nabha
    • 1
  • Natasha Atanaskova
    • 1
  1. 1.Department of PathologyWayne State University School of MedicineDetroitUSA

Personalised recommendations